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Abstract
Stroke patients diagnosed with Atrial Fibrillation are at a
significantly increased risk of recurrent strokes secondary to
this abnormal heart rhythm. The standard first-line treatment
for atrial fibrillation and stroke prevention includes
anticoagulation therapy, such as warfarin or novel oral
anticoagulants.. Novel oral anticoagulants have become the
preferred choice of anticoagulation in recent years , however
the question still remains if they are superior at preventing
recurrent strokes when compared to warfarin. This research
hopes to determine in stroke patients diagnosed with atrial
fibrillation (P), are novel oral anticoagulants (NOACs) (I)
actually more effective at preventing recurrent strokes (O)
when compared to warfarin(C)?

Introduction
● Stroke is the 3rd leading cause of death and the 1st
leading cause of long-term disability in the US
● Occurs when blood supply to the brain is interrupted and
leads to lack of oxygen and nutrients to the brain
● Major risk factor for developing strokes is an abnormal
heart rhythm called Atrial Fibrillation (AF)
● Stroke patients with a cardioembolic etiology, such as AF
are at a significantly higher risk of recurrent strokes
● For many years, warfarin has been the anticoagulation
therapy of choice for recurrent stroke prevention in AF
patients
● However, with novel oral anticoagulants (NOACs) now on
the market, there has been a significant deterrence in the
use of warfarin as stroke prevention therapy
● Although NOACs have been said to have a more desirable
side effect profile and are associated with less bleeding
risks than warfarin, it is still unclear if NOACs are
superior to warfarin in preventing subsequent
cardioembolic strokes

Methods
A literature search was performed in November 2019 using
Pubmed, Google Scholar, and Academic Search Ultimate to
compile six articles with the most relevant and applicable
research. Inclusion and exclusion criteria were applied to the
search in order to compile the most appropriate articles in
regards to the proposing question.

Results

Discussion

1. Arihiro S, Todo K, Koga M, et al. Three-month risk-benefit profile of anticoagulation after stroke with
atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. International Journal of
Stroke. 2016;11(5):565-574. doi:10.1177/1747493016632239

- Researchers looked at 1,137 patients who were hospitalized with ischemic stroke/TIA and
diagnosed with AF who were started on different anticoagulation, and compared number of
recurrent ischemic events in those started on warfarin, dabigatran, rivaroxaban, or apixaban
2. Diener H-C, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with
atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY
trial. The Lancet Neurology. 2010;9(12):1157-1163. doi:10.1016/s1474-4422(10)70274-x

-RCT of 18, 113 AF patients assigned to receive dabigatran or warfarin and followed for 2
years to assess for recurrent strokes
3. Garcia DA, Wallentin L, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation
according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal. 2013;166(3):549-558.
doi:10.1016/j.ahj.2013.05.016

- RCT of 18, 201 patients with AF assigned to take apixaban, warfarin, or placebo to test
efficacy in preventing stroke or systemic embolism
4. Hong K-S, Kwon SU, Lee SH, et al. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After
Atrial Fibrillation–Related Mild Ischemic Stroke. JAMA Neurology. 2017;74(10):1206.
doi:10.1001/jamaneurol.2017.2161

- RCT of 195 patients with acute cardioembolic strokes secondary to AF designed to determine
whether rivaroxaban or warfarin was more effective at preventing subsequent strokes
5. Kanai Y, Oguro H, Tahara N, et al. Analysis of Recurrent Stroke Volume and Prognosis between
Warfarin and Four Non–Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary
Prevention of Stroke. Journal of Stroke and Cerebrovascular Diseases. 2018;27(2):338-345.
doi:10.1016/j.jstrokecerebrovasdis.2017.09.007

- Investigated the volume and number of recurrent strokes in 101 patients with nonvalvular
atrial fibrillation who were treated with non-vitamin K antagonist oral anticoagulants and
compared outcomes to patients receiving warfarin
6. Rost NS, Giugliano RP, Ruff CT, et al. Outcomes With Edoxaban Versus Warfarin in Patients With
Previous Cerebrovascular Events. Stroke. 2016;47(8):2075-2082. doi:10.1161/strokeaha.116.013540

- RCT of 5,973 AF patients with previous ischemic stroke/TIA designed to investigate and
compare the efficacy of edoxaban with warfarin in reducing the risk of recurrent stroke
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On the basis of these results, all 6 of the studies
found that the efficacy of novel oral anticoagulation
was comparable to that of warfarin. However, only
two of the studies provided enough statistical
evidence to determine that novel oral anticoagulation
was significantly more effective at preventing strokes
when compared to warfarin (Diener and Garcia.) The
study conducted by Kanai suggested that
administering NOACs after a stroke event may not
reduce infarct recurrence, but it may reduce recurrent
infarct volume when compared to warfarin. One
major deficit across all studies was the timeline and
duration of intervention. The stroke risk associated
with AF and prior cerebrovascular accidents is a
lifelong risk and requires long term follow up and
management.

Conclusion
The studies compiled for this meta-analysis all
demonstrated that warfarin and novel oral
anticoagulation are comparable in regards to efficacy
in recurrent stroke prevention. Some research showed
promising evidence that NOAC patients experienced
less recurrent ischemic stroke events and lower
volumes of strokes. Though the evidence is not
overwhelming enough to determine that NOACs
should be the drug of choice, it provides insight for
further research for more definitive data. Future
studies would have much more power and
significance if they could obtain a larger, more
diverse sample population, as well as longer follow
up. Ultimately, this analysis demonstrated that no one
anticoagulant can be determined the “gold standard”
when reducing stroke risk in patients with AF. While
warfarin and NOACs are comparable in regards to
efficacy, there are many other factors that must be
considered on a case by case basis. The choice of
anticoagulant should be individualized to the patient,
based on their individual risk factors, comorbidities,
insurance, and personal preference.

